menu
    • menu
    [{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Calyptus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Provepharm Life Solutions \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"American Regent","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Guanylate cyclase (GC)","graph1":"Hematology","graph2":"Approved FDF","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Provepharm Life Solutions \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"3,3\\'-Dioxo-2,2\\'-bisindolylidene-5,5\\'-disulfonate Disodium","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"A.forall","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Provepharm Life Solutions \/ A.forall","highestDevelopmentStatusID":"15","companyTruncated":"Provepharm Life Solutions \/ A.forall"}]

    Find Clinical Drug Pipeline Developments & Deals by Provence Technologies SAS

    Menu

    Provence Technologies SAS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : A.forall

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            A.forall Expands US Generics Portfolio

                            Details : With the acquisition, A.forall considerably extends its marketed portfolio in the US, including Dihydroergotamine Mesylate, for the treatment of migraine and cluster headaches.

                            Product Name : Dihydroergotamine Mesylate-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 09, 2025

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : A.forall

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indigo Carmine

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Pat...

                            Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ureteral Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 07, 2024

                            Lead Product(s) : Indigo Carmine

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indigo Carmine

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indigotindisulfonate Sodium Injection, USP As an Aid in the Determination of Ureteral Patency in Patient's wit...

                            Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ureteral Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 16, 2023

                            Lead Product(s) : Indigo Carmine

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indigo Carmine

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

                            Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ureteral Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2023

                            Lead Product(s) : Indigo Carmine

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Calyptus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Calyptus Pharmaceuticals Announces Partnership with Provepharm to Accelerate Development of an Acute Care Inje...

                            Details : Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.

                            Product Name : Cetrorelix Acetate-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 22, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Calyptus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylene Blue

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Recipient : American Regent

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            American Regent Launches a New Vial Presentation

                            Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.

                            Product Name : ProvayBlue

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2022

                            Lead Product(s) : Methylene Blue

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Recipient : American Regent

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed

                            Provepharm Life Solutions

                            France arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3,3\'-Dioxo-2,2\'-bisindolylidene-5,5\'-disulfonate Disodium

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

                            Details : 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate Disodium is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ureteral Injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 14, 2020

                            Lead Product(s) : 3,3\'-Dioxo-2,2\'-bisindolylidene-5,5\'-disulfonate Disodium

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth